An increased risk of inflammatory bowel disease with combined oral contraceptives and HRT will be noted in product information, the TGA has said in its latest Medicines Safety Update. The agency said it had looked at international research that had reported links between the medications and an increased risk of diseases like ulcerative colitis and Crohn’s disease. The TGA is negotiating with the sponsors of COCs and oestrogen/progestogen combination HRT products to “ensure adequate information is provided in their product information,” it said.